Vancomycin Pharmacology and Glycopeptide Antibiotics
1. University of Kufa
College of Medicine
Department of pharmacology & therapeutics
Done by :-
Qassim A. Zigum
2. OUTLINE
ď˘ INTRODUCTION
ď˘ HISTORY
ď˘ VANCOMYCIN
ââ Mechanisms of Action
ââ Mechanisms of Resistance
ââ Antibacterial Activity
ââ Pharmacokinetics
ââ Clinical Uses
ââ Adverse Reactions
ď˘ OTHER GLYCOPEPTIDES 2
3. INTRODUCTION
ď˘ Glycopeptide are non-beta lactam cell wall
synthesis inhibitors antibiotics .
ď˘ are composed of glycosylated cyclic or
polycyclic nonribosomal peptides.
ď˘ include the :-
ââ anti â infective antibiotics ( vancomycin ,
teicoplanin, and telavancin)
ââ anti â tumor antibiotic ( bleomycin )
3
4. HISTORY
ď˘ Vancomycin was isolated in 1953, and used
clinically from 1955. Approved in 1958 by FDA to
treat penicillin resistant staphylococci. MRSA first
seen in 1961.
ď˘ Bleomycin was first discovered in 1966.
ď˘ Teicoplanin was discovered in the early 1990s.
ď˘ Telavancin is a semi-
synthetic lipoglycopeptide derivative of vancomycin
(approved by FDA in 2009).
4
5. VANCOMYCIN
ď˘ Vancomycin is an antibiotic produced by
Streptococcus orientalis and Amycolatopsis
orientalis.
ď˘ With the exception of Flavobacterium , it is active
only aginst gram-positive bacteria.
ď˘ Vancomycin is a glycopeptide of molecular weight
1500 dalton . It is water soluble and quite stable.
5
6. MECHANISMS OF ACTION
ď˘ Vancomycin inhibits cell wall synthesis by binding
firmly to the D-Ala-D-Ala terminus of nascent
peptidoglycan pentapeptide .
ď˘ This inhibits the transglycosylase, preventing
further elongation of peptidoglycan and cross-
linking.
ď˘ The peptidoglycan is thus weakened, and the cell
becomes susceptible to lysis.
ď˘ The cell membrane is also damaged, which
contributes to the antibacterial effect.
6
8. BASES OF RESISTANCE
ď˘ Changing the D-Ala-D-Ala unite of the
peptidoglycane to D-Ala-D-Lactate which cannot be
bond to vancomycin.
ď˘ This results in the loss of a critical hydrogen bond
that facilitates high affinity binding of vancomycin to
its target and loss of activity.
8
9. BASES OF RESISTANCE
9
R
O
N
H
O
H CH3
O
O
O
H CH3
R
O
N
H
H
N
H CH3
O
O
H CH3
O
C-Terminus of D-Ala-D-Ala peptide
C-Terminus of D-Ala-D-Lactate peptide
10. ANTIBACTERIAL ACTIVITY
ď˘ Vancomycin is bactericidal for gram-positive bacteria in
concentrations of 0.5â10 mcg/mL.
ď˘ Most pathogenic staphylococci, including those
producing β lactamase and those resistant to nafcillin
and methicillin, are killed by 2 mcg/mL or less.
ď˘ Vancomycin kills staphylococci relatively slowly and
only if cells are actively dividing; the rate is less than
that of the penicillins both in vitro and in vivo.
ď˘ Vancomycin is synergistic in vitro with gentamicin and
streptomycin against Enterococcus faecium and
Enterococcus faecalis strains that do not exhibit high
levels of aminoglycoside resistance.
10
12. PHARMACOKINETICS
ď˘ Vancomycin is poorly absorbed from the
intestinal tract and is administered orally only for
the treatment of antibiotic-associated colitis caused
by C. difficile .
ď˘ Parenteral doses must be administered
intravenously. A 1-hour intravenous infusion of 1 g
produces blood levels of 15â30 mcg/mL for 1â2
hours.
ď˘ The drug is widely distributed in the body.
Cerebrospinal fluid levels 7â30% of simultaneous
serum concentrations are achieved if there is
meningeal inflammation. 12
13. PHARMACOKINETICS
ď˘ Ninety percent of the drug is excreted by glomerular
filtration.
ď˘ The drug has a serum elimination half-life of about
6 hours.
ď˘ In the presence of renal insufficiency, striking
accumulation may occur .
ď˘ In functionally a nephric patients, the half-life of
vancomycin is 6â10 days.
ď˘ A significant amount (roughly 50%) of vancomycin
is removed during a standard hemodialysis run
when a modern, high-flux membrane is used.
13
15. CLINICAL USES
ď˘ Blood stream infections and endocarditis caused by
methicillin-resistant staphylococci MRSA.
ď˘ enterococcal endocarditis in a patient with serious
penicillin allergy( in combination with gentamicin) .
ď˘ meningitis suspected or known to be caused by a
penicillin-resistant strain of pneumococcus(in
combination with cefotaxime, ceftriaxone, or
rifampin)
ď˘ Oral vancomycin, 0.125â0.25 g every 6 hours, is
used to treat antibiotic
associated pseudomembranous colitis caused by
C. difficile .
15
16. ADVERSE REACTIONS
ď˘ Adverse reactions are encountered in about 10% of
cases (Most reactions are minor).
ď˘ Vancomycin is irritating to tissue, resulting in
phlebitis at the site of injection.
ď˘ Chills and fever may occur.
ď˘ Ototoxicity is rare and nephrotoxicity uncommon
with current preparations.
ď˘ âred manâ or âred neckâ syndrome.
16
18. OTOTOXICITY AND NEPHROTOXICITY
ď˘ Ototoxicity is rare and nephrotoxicity
uncommon with current preparations.
ď˘ However, administration with
another ototoxic or nephrotoxic drug,
such as an aminoglycoside, increases
the risk of these toxicities.
ď˘ Ototoxicity can be minimized by maintaining
peak serum concentrations below 60 mcg/mL.
18
19. âRED MANâ OR âRED NECKâ SYNDROME.
ď˘ This infusion-related flushing is
caused by release of histamine.
ď˘ It can be largely prevented by
prolonging the infusion period
to 1â2 hours or pretreatment
with an antihistamine such as
diphenhydramine.
19
20. TEICOPLANIN
ď˘ Teicoplanin is a glycopeptide antibiotic that is very
similar to vancomycin in mechanism of action and
antibacterial spectrum.
ď˘ Unlike vancomycin, it can be given intra- muscularly
as well as intravenously.
ď˘ Teicoplanin has a long half-life (45â70 hours),
permitting once-daily dosing .
ď˘ This drug is available in Europe but has not been
approved for use in the United States.
20
21. TELAVANCIN
ď˘ Telavancin is a semisynthetic lipoglycopeptide
derived from vancomycin.
ď˘ The half-life of telavancin is approximately 8 hours,
which supports once-daily intravenous dosing.
ď˘ Telavancin is approved for treatment of complicated
skin and soft tissue infections at a dose of 10 mg/kg
IV daily.
ď˘ Telavancin is potentially teratogenic, so
administration to pregnant women must be avoided.
21
22. DALBAVANCIN
ď˘ Dalbavancin is a semisynthetic lipoglycopeptide
derived from teicoplanin.
ď˘ It is not active against most strains of vancomycin-
resistant enterococci.
ď˘ Dalbavancin has an extremely long half-life of 6â11
days, which allows for onceweekly intravenous
administration.
ď˘ Development of dalbavancin has been put on hold
pending additional clinical trials.
22